PO Box 163154
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, secretory otitis media and CVID sinusitis.
CEO: Joseph D. Kittle Jr., PhD
CSO: Tom Zupancic, PhD
Please click here for clinical trial information.